MDACC Study No:2013-0814(2012-0513MELANOMA) ( NCT No: NCT01693562)
Title:A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors (2012-0513)
Principal Investigator:Wen-Jen Hwu
Treatment Agent:MEDI4736
Study Status:Open
Study Description:The goal of this clinical research study is to learn about the safety of
MEDI4736 when given to patients with advanced solid tumors. Researchers also
want to learn if MEDI4736 can help to control the disease. This study will
also evaluate how much MEDI4736 is in your blood at various times, whether your
immune system become activated following treatment or your body produces
antibodies (proteins produced by your immune system) against MEDI4736, as well
as the effect MEDI4736 has on your cancer.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase I
Treatment Agents:MEDI4736
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:MedImmune
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Wen-Jen Hwu
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults